Development of Human Laboratory Study Model of Cocaine Relapse Prevention. - 1
The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2004 by National Institute on Drug Abuse (NIDA).
Recruitment status was Active, not recruiting
Information provided by:
National Institute on Drug Abuse (NIDA)
First received: June 18, 2002
Last updated: October 23, 2007
Last verified: September 2004
The purpose of this study is to assess the development of human laboratory study model of cocaine relapse prevention.
Procedure: Cocaine (IV)
||Intervention Model: Parallel Assignment
Primary Purpose: Treatment
||Development of Human Laboratory Study Model of Cocaine Relapse Prevention
Primary Outcome Measures:
- Cocaine craving
- Cocaine related high
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
The primary objective of this study will be to develop experimental procedures and parameters demonstrating arousal and craving responses to cocaine-related environmental cues as a model for future testing of the relapse prevention medication treatment of cocaine addiction.
|Ages Eligible for Study:
||18 Years to 55 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Cocaine dependent, non treatment seeking individuals
Please contact site directly for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00040066
|UCLA Integrated Substance Abuse Program
|Los Angeles, California, United States, 90024 |
|University of Texas Health Science Center
|San Antonio, Texas, United States, 78284 |
||John Roache, Ph.D.
||National Institute on Drug Abuse (NIDA)
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||June 18, 2002
||October 23, 2007
||United States: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 23, 2014
Central Nervous System Agents
Central Nervous System Depressants
Dopamine Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Physiological Effects of Drugs
Sensory System Agents